Free tool
Drug Search
Every brand-name drug and biologic application (NDA or BLA) in Drugs@FDA: 5,899 in all. Generic (ANDA) applications are not listed; their reference drug is.
Last checked: Nov 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
3 matches for "Ascendis"
Brand names that start with your search come first, then marketed and novel drugs.
| Drug | Sponsor | Application | First approved | Programs |
|---|---|---|---|---|
| Skytrofa Lonapegsomatropin-Tcgd | Ascendis Pharma Encocrinology Div A/S | BLA761177 | Aug 25, 2021 | NovelOrphan |
| Yuviwel Navepegritide | Ascendis | NDA219164 | Feb 27, 2026 | NovelAccelerated approvalPriority reviewOrphan |
| Yorvipath Palopegteriparatide | Ascendis Pharma Bone | NDA216490 | Aug 9, 2024 | NovelPriority reviewOrphan |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.